

Kris Looney Promoted To President of Selenium, Ltd.

LUBBOCK & AUSTIN, TX – July 13, 2009 -- Emergent Technologies, Inc. (ETI) announced today that Kris Looney has been promoted to President of the bioscience company Selenium, Ltd, from his former position as Executive Vice President and Managing Director of the company. Thomas A. Harlan remains the Chief Executive Officer of Selenium. Selenium, Ltd. is focused on the collaborative development and commercialization of its selenium-based technology platform. The Selenium technology provides surface coatings that act as an impenetrable barrier to microbes and can also be used to arm therapeutics to selectively destroy targeted cells.

Selenium CEO Harlan stated, "Kris is eminently well-suited to guide Selenium, Ltd. in the next stage of the company's growth and success. His promotion is designed to help form additional relationships with market leaders as Selenium strengthens its position in the medical device coating industry and continues to develop coatings for industrial and consumer product applications as well as methods for arming targeted therapeutics."

In his role as company president, Kris Looney will continue to lead the commercialization and ongoing development of Selenium's antimicrobial coatings and therapeutic arming applications. "It is an exciting time for Selenium," said Looney. "Our antimicrobial technology's broad applicability serves the needs of multiple industries and we are discussing license opportunities for a number of applications. Market interest in our coatings has exploded since one of our partners, ClassOne Orthodontics, received FDA approval and a CE Mark for the new dental product, selenium-coated SeLECT Defense."

Kris Looney joined Emergent Technologies, Inc. (ETI) in July of 2005 as Business Development Director. He also served as Executive Vice President and Managing Director of ETI's portfolio company, Selenium, Ltd. Prior to joining ETI, Looney was Chief Financial Officer of Transformation Enzyme Corporation, where he was pivotal in the financial management and entrepreneurial business development that enabled the start-up company to become an industry leader in the nutritional supplement market. Looney has a BA degree in Marketing and an MBA from the University of Texas at Austin.

About Selenium, Ltd.

Selenium, Ltd. was founded in 2004 based on discoveries made by Julian Spallholz, Ph.D. and Ted Reid, Ph.D. at Texas Tech University. Their work revealed that certain organoselenium molecules are catalytic and produce super oxide radicals, resulting in lethal, but short range toxicity to surrounding cells. Thus, Selenium coated surfaces act as an impenetrable barrier to microbes and other cells, and selenium armed molecules will selectively destroy targeted cells.

Page 2 of 2 - Kris Looney Promoted To President of Selenium, Ltd.

Selenium, Ltd. is an Emergent Technologies Inc. (ETI) portfolio company, and ETI provides all management services. For more information, visit the company website www.selenbio.com

About Emergent Technologies, Inc.

Headquartered in Austin, Texas, Emergent Technologies, Inc. (ETI) is a life sciences technology investment and management company which provides early stage funding and development for scientific discoveries originating at universities and research institutions. The Company creates value by transforming scientific breakthroughs into technology platforms with multiple applications. ETI's unique innovation process enables the Company to select promising scientific discoveries for development, maximize the value of intellectual property and manage both cost and risk associated with the commercial development of early stage technologies. ETI is dedicated to turning research into revenue and, in the process, introducing compelling solutions to meet important market needs. For more information, visit the company website www.etibio.com

###

Media Contact:

Sandra Oak

Phone: 321-591-1508 Email: soak@nsightpr.com